BASEL, Jan. 19, 2023, a clinical stage immuno-oncology company owned by PPF Group, announced today that the first patient was dosed in its Phase 2 AURELIO-05 combination trial of nanrilkefusp alfa
XBiotech Announces First Patient Enrolled into the French National Cancer Institute (INCA) Sponsored Phase I/II/III Clinical Study for Natrunix™ Therapy for Colorectal Cancer streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
INCA funded Phase I/II/III Study for Natrunix in Combination with Trifluridine/Tipiracil, the TASKIN Study, Launches at 20 Leading Medical Centers in FranceAUSTIN, Texas, Oct. 13, 2022 (GLOBE NEWSWIRE)
STOCKHOLM, June 9, 2022 /PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM CET), focusing
/PRNewswire/ Cantargia (Cantargia AB; Nasdaq Stockholm: CANTA) today announced it will host an R&D Day on Thursday, June 16, 2022 at 09:00 AM EDT (3:00 PM.